Published in Br J Pharmacol on December 11, 2006
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv (2011) 1.38
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci (2008) 1.30
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2008) 1.28
Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol (2011) 1.20
Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol (2007) 1.15
A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci (2008) 1.13
Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol (2007) 1.12
Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol (2011) 1.10
Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. J Proteome Res (2008) 1.06
Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol (2008) 1.01
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology (2010) 0.99
Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation. J Neurophysiol (2008) 0.98
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol (2010) 0.98
Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett (2008) 0.96
The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res (2008) 0.92
The dynamic nature of type 1 cannabinoid receptor (CB(1) ) gene transcription. Br J Pharmacol (2012) 0.88
Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica (2011) 0.88
Effects of gonadal hormones on the peripheral cannabinoid receptor 1 (CB1R) system under a myositis condition in rats. Pain (2012) 0.87
Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. AAPS J (2010) 0.87
Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg (2010) 0.86
Desensitization of transient receptor potential ankyrin 1 (TRPA1) by the TRP vanilloid 1-selective cannabinoid arachidonoyl-2 chloroethanolamine. Mol Pharmacol (2011) 0.83
Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitis. J Urol (2013) 0.82
Activation of cannabinoid receptor 2 inhibits experimental cystitis. Am J Physiol Regul Integr Comp Physiol (2013) 0.81
Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain. Br J Pharmacol (2009) 0.80
Acute resistance exercise induces antinociception by activation of the endocannabinoid system in rats. Anesth Analg (2014) 0.80
CB1 cannabinoid receptor agonist prevents NGF-induced sensitization of TRPV1 in sensory neurons. Neurosci Lett (2013) 0.80
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology (2017) 0.78
Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sci (2012) 0.78
Investigational pharmacology for low back pain. J Pain Res (2010) 0.77
Functional role of cannabinoid receptors in urinary bladder. Indian J Urol (2010) 0.76
The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids. PLoS One (2011) 0.76
The role of peripheral cannabinoid receptors type 1 in rats with visceral hypersensitivity induced by chronic restraint stress. J Neurogastroenterol Motil (2010) 0.76
Retracted The novel therapeuthic targets in the treatment of chronic pain. Transl Med UniSa (2012) 0.75
Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods (1994) 23.05
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 18.17
Ethical guidelines for investigations of experimental pain in conscious animals. Pain (1983) 17.70
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 5.30
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol (1992) 2.80
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain (1998) 2.43
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci (2003) 2.25
Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: behavioral evidence. Pain (1996) 2.12
Two types of C nociceptors in human skin and their behavior in areas of capsaicin-induced secondary hyperalgesia. J Neurophysiol (2004) 2.01
Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: electrophysiological evidence. Pain (1996) 1.95
Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature (1996) 1.94
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci (2006) 1.80
Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience (2005) 1.76
Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience (1999) 1.73
Sensitization of high mechanothreshold superficial dorsal horn and flexor motor neurones following chemosensitive primary afferent activation. Pain (1994) 1.70
Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther (1999) 1.67
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol (1996) 1.61
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience (2000) 1.56
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 1.55
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci (2004) 1.40
Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience (1999) 1.37
Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology (2001) 1.35
Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther (1994) 1.33
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 1.33
Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience (2003) 1.27
A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.23
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther (2003) 1.20
Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids (2002) 1.17
Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain (2005) 1.14
Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys Lipids (2002) 1.12
Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci (2000) 1.01
Time-course of spinal sensitization following carrageenan-induced inflammation in the young rat: a comparative electrophysiological and behavioural study in vitro and in vivo. Neuroscience (1999) 0.97
From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther (2002) 0.95
Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol (2001) 0.93
Neural mechanisms of cutaneous nociceptive pain. Clin J Pain (2000) 0.87
Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. Eur J Neurosci (2003) 0.87
Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A (1999) 5.11
Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 3.16
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 2.73
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
Altered nociceptive neuronal circuits after neonatal peripheral inflammation. Science (2000) 2.28
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol (1996) 1.78
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry (2012) 1.63
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol (2005) 1.48
AM630, a competitive cannabinoid receptor antagonist. Life Sci (1995) 1.46
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol (2003) 1.44
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem (1999) 1.44
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44
Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci (1997) 1.42
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Structure and orientation of the pore-forming peptide, melittin, in lipid bilayers. J Mol Biol (1994) 1.39
(R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) (2001) 1.36
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 1.33
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther (1999) 1.26
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol (1997) 1.25
The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology (2001) 1.24
A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.23
Structural requirements for cannabinoid receptor probes. Handb Exp Pharmacol (2005) 1.22
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 1.21
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur J Pharmacol (1995) 1.17
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem (1998) 1.16
Characterization of the L lambda phase in trehalose-stabilized dry membranes by solid-state NMR and X-ray diffraction. Biochemistry (1989) 1.15
Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun (1997) 1.14
The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berl) (2005) 1.13
Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem (1996) 1.12
Deuterium NMR investigation of ether- and ester-linked phosphatidylcholine bilayers. Biochemistry (1985) 1.12
Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci (1996) 1.11
Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol (1997) 1.11
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem (1998) 1.11
Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology (Berl) (2007) 1.11
Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol (1997) 1.07
AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci (1997) 1.04
The neurobiology of cannabinoid analgesia. Life Sci (1999) 1.02
Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta (1995) 1.01
Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res (1998) 1.01
Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci (1999) 1.00
Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett (1997) 0.99
Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol (2010) 0.99
Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology (Berl) (1998) 0.98
Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. Biol Reprod (1998) 0.98
AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci (1998) 0.97
A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci (1995) 0.95
Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol (2009) 0.95
Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse (2000) 0.94
(-)-11-Hydroxy-7'-isothiocyanato-1',1'-dimethylheptyl-delta 8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain. J Med Chem (1994) 0.93
Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC. Pharmacol Biochem Behav (1993) 0.93
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav (2010) 0.92
The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav (2010) 0.92
Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues. J Med Chem (1998) 0.92
5'-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor. J Med Chem (1992) 0.91
Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs. J Med Chem (1996) 0.91
A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology (Berl) (1998) 0.91
Amphipathic interactions of cannabinoids with membranes. A comparison between delta 8-THC and its O-methyl analog using differential scanning calorimetry, X-ray diffraction and solid state 2H-NMR. Biochim Biophys Acta (1992) 0.90
Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem (2001) 0.90
Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience (1996) 0.90
Autoradiographic distribution of [3H](+)-pentazocine and [3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: a comparative study. Brain Res (1992) 0.90
The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. Neuroscience (2011) 0.90
Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav (2008) 0.90
The effect of cholesterol on lipid dynamics and packing in diether phosphatidylcholine bilayers. X-ray diffraction and 2H-NMR study. Biochim Biophys Acta (1987) 0.89
(-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behav Pharmacol (2004) 0.89
Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. Behav Pharmacol (2000) 0.89
Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol (2012) 0.89
Study of the topography of cannabinoids in model membranes using X-ray diffraction. Biochim Biophys Acta (1990) 0.89
High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. Anal Biochem (1996) 0.89
Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. J Pept Res (2005) 0.88
A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. Br J Pharmacol (2008) 0.88
Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols. J Med Chem (1998) 0.88
The novel cannabinoid agonist AM 411 produces a biphasic effect on accuracy in a visual target detection task in rats. Behav Pharmacol (2005) 0.88
PET studies in the primate brain and biodistribution in mice using (-)-5'-18F-delta 8-THC. Pharmacol Biochem Behav (1991) 0.88
Molecular probes for the cannabinoid receptors. Chem Phys Lipids (2000) 0.87
Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system. J Pept Res (2004) 0.87
Effects of the anesthetic steroid alphaxalone and its inactive delta 16-analog on the thermotropic properties of membrane bilayers. A model for membrane perturbation. Biochim Biophys Acta (1995) 0.87
Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). Eur J Pharmacol (1999) 0.87
Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats. Neuroscience (2010) 0.87
Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil (2010) 0.87
Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology (Berl) (2009) 0.86
Geometric requirements for membrane perturbation and anesthetic activity. Conformational analysis of alphaxalone and delta 16-alphaxalone and 2H NMR studies on their interactions with model membranes. Mol Pharmacol (1985) 0.86
Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav (2008) 0.86
Pharmacological evaluation of halogenated delta 8-THC analogs. Pharmacol Biochem Behav (1991) 0.86
Topography of alphaxalone and delta 16-alphaxalone in membrane bilayers containing cholesterol. Biochim Biophys Acta (1994) 0.85
Novel conformationally restricted tetracyclic analogs of delta8-tetrahydrocannabinol. Bioorg Med Chem Lett (1999) 0.85
Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bull Exp Biol Med (2002) 0.85
Ligand based structural studies of the CB1 cannabinoid receptor. J Pept Res (2002) 0.85
The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J Biol Chem (1996) 0.85